Study of Weekly Cabazitaxel for Advanced Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

July 31, 2016

Conditions
Hormone Refractory Prostate Cancer
Interventions
DRUG

Cabazitaxel 10 mg/m2

Cabazitaxel 10 mg/m2 in a 1-hour infusion on days 1, 8, 15 and 22 of 5-week cycles.

Trial Locations (12)

15706

Complejo Hospitalario Universitario de Santiago, Santiago de Compostela

28007

Hospital General Universitario Gregorio Marañón, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28922

Hospital Universitario Fundación Alcorcón, Alcorcón

32005

Complejo Hospitalario de Ourense, Ourense

41013

Hospital Virgen Del Rocío, Seville

41014

Hospital Nuestra Señora de Valme, Seville

46009

Fundación Instituto Valenciano de Oncología, Valencia

46014

Consorcio Hospital General Universitario de Valencia, Valencia

08908

Institut Català D'Oncologia L'Hospitalet (Ico), L'Hospitalet de Llobregat

08243

Hospital de Sant Joan de Déu, Manresa

08036

Hospital Clinic I Provincial de Barcelona, Barcelona

All Listed Sponsors
lead

Spanish Oncology Genito-Urinary Group

OTHER

NCT01518283 - Study of Weekly Cabazitaxel for Advanced Prostate Cancer | Biotech Hunter | Biotech Hunter